Review Article|Articles in Press, 103683

Therapeutic apheresis in ANCA Associated Vasculitis: Current status of Pexivas

Published:February 24, 2023DOI:
      Pexivas is a Randomized Control Trial launched in June 2010 – recruitment stopped in September 2016, where 704 patients with ANCA Associated Vasculitis (AAV) presenting with eGFR lower than 50 ml/min were randomized to additional PLEX (PLEX) and two steroid protocols and followed on average 2.9 years. The results were published in 2020 [
      • Walsh M.
      • Merkel P.A.
      • Peh C.A.
      • Szpirt W.M.
      • et al.
      Plasma exchange and glucocorticoids in Severe ANCA Associated Vasculitis.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Walsh M.
        • Merkel P.A.
        • Peh C.A.
        • Szpirt W.M.
        • et al.
        Plasma exchange and glucocorticoids in Severe ANCA Associated Vasculitis.
        N Engl J Med. 2020; 382: 622-631
        • Walsh M.
        • Collister D.
        • Zeng L.
        • Merkel P.
        • Pusey C.D.
        • Guyatt G.
        • Peh C.A.
        • Szpirt W.
        • Ito-Hara T.
        • Jayne D.R.W.
        The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis.
        BMJ. 2022; : 376
        • Kaplan A.A.
        • Szpirt W.M.
        Should we still use therapeutic PLEX for rapidly progressive glomerulonephritis in ANCA Associated Vasculitis?.
        Kidney Dial. 2022; 2 (40): 399-406
      1. Fussner L..Proceedings of 2022 International Vasculitis and ANCA Workshop, 3–6 April 2022.

        • Gulati K.
        • Edwars H.
        • Prendecki M.
        • et al.
        Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis.
        Kidney Int. 2021; 100: 1316-1324
        • Walters G.D.
        • Narelle S.W.
        • Cooper T.E.
        • Craig J.
        Interventions for renal vasculitis in adults.
        Cochrane Database Syst Rev. 2020; 1CD003232
        • Yamada Y.
        • Harada M.
        • Hara Y.
        • Iwabuchi R.
        • et al.
        Efficacy of plasma exchange for antineutrophil cytoplasmic antibody-associated systemic vasculitis: a systematic review and meta-analysis.
        Arthritis Res Ther. 2021; 23: 28
      2. Bellos I., Boletis I., Lionaki S., A Meta-Analysis of the Safety and Efficacy of Maintenance Therapies for Antineutrophil Cytoplasmic Antibody Small-Vessel Vasculitis.Clin Rheumatol. 2021;40:1447–56.

        • Balogun R.A.
        • Sanchez A.P.
        • Klingel R.
        • Witt V.
        Update to the ASFA guidelines on the use of therapeutic apheresis in ANCA-associated vasculitis.
        J Clin Apher. 2020; 35 (10.1002/jca.21820. Epub 2020 Aug 7): 493-499
        • Aqeel F.
        • Xu L.
        • Tomar O.
        • Duchen J.
        • Li T.
        • Geetha D.
        Practice patterns of induction therapy in severe anti-neutrophil cytoplasmic Autoantibody-Associated Vasculitis.
        Kidney Int Rep. 2022; 7: 2704-2708